Encouraging High-Pressure Slurry Ablation Test Results at Myriad's Copper Mountain Uranium Project

Myriad reports initial uranium concentration testing, but provides no quantitative results.

What the company is saying

Myriad Uranium Corp. (CSE:M, OTCQB:MYRUF, FSE:C3Q) announces that DISA Uranium™ Corporation completed an initial testing campaign in 2026 using samples from Myriad. The stated purpose was to assess how efficiently DISA's high-pressure slurry ablation technology (HPSA™) could concentrate uranium from these samples. The announcement frames this as a milestone in evaluating the technology's applicability to Myriad's material. No specific grades, recoveries, or economic implications are disclosed. The company does not provide executive commentary or attribute the results to any individual. The tone is strictly factual, with no promotional language or forward-looking statements.

What the data suggests

The only hard facts disclosed are the completion of a 2026 testing campaign and the use of DISA Uranium's HPSA™ technology on Myriad's samples. No uranium grades, recovery rates, or quantitative performance metrics are provided. There is no information on whether the technology met, exceeded, or fell short of expectations. No project names, resource estimates, or financial figures are included. The absence of quantitative results means investors cannot assess the impact on Myriad's asset value or the viability of the technology for commercial use. The disclosure is minimal and does not enable any assessment of progress beyond the fact that testing occurred.

Analysis

The announcement is strictly factual, reporting the completion of an initial testing campaign using DISA Uranium's HPSA™ technology on samples from Myriad Uranium. No forward-looking statements, projections, or aspirational claims are present. There is no promotional or exaggerated language, and the tone remains neutral throughout. The absence of quantitative results or financial figures means the update is informational only, with no attempt to inflate investor expectations. There is no mention of capital outlay, future benefits, or timelines beyond the completed testing. The gap between narrative and evidence is minimal, as the announcement simply states what has occurred without embellishment.

Risk flags

• ●The lack of quantitative results—such as uranium grades or recovery rates—prevents investors from evaluating the effectiveness of DISA's HPSA™ technology on Myriad's samples. This omission creates uncertainty about whether the technology adds value or is suitable for Myriad's assets.
• ●No resource, financial, or economic data is disclosed, leaving the impact of the testing campaign on Myriad's future prospects undefined. This limits the ability to assess progress or benchmark against peer disclosures.
• ●The absence of executive commentary or stated next steps means there is no guidance on how these results will inform future work or decision-making, increasing uncertainty about the company's operational roadmap.

Bottom line

This announcement confirms that initial testing of DISA Uranium's HPSA™ technology on Myriad's samples was completed in 2026, but provides no quantitative results or economic implications. Investors have no basis to judge whether the technology is effective or commercially relevant for Myriad's assets. The lack of detail means this update is not actionable and does not advance the investment case. For this to become meaningful, Myriad would need to disclose specific uranium grades, recovery rates, or a clear plan for integrating the technology into its projects. The most important takeaway is that, without numbers, the announcement offers little insight into value creation or technical progress.

Announcement summary

(CSE:M) (OTCQB:MYRUF) (FSE:C3Q) Myriad Uranium Corp. announced the results of an initial testing campaign conducted by DISA Uranium™ Corporation in 2026 using samples from Myriad Uranium. The primary objective of the testing was to determine how efficiently DISA's high-pressure slurry ablation technology (HPSA™) could concentrate uranium from the provided samples. The announcement states that the testing campaign was completed in 2026. The samples tested were sourced from Myriad Uranium. The results pertain specifically to the application of DISA Uranium's HPSA™ technology. The announcement does not provide specific figures, grades, recoveries, or quantitative results from the testing campaign. No additional project names, permit numbers, or counterparties are mentioned in the provided text. The announcement does not include any executive quotes or attributions. No financial figures, production volumes, or resource estimates are disclosed in the provided text. The announcement is focused solely on the initial testing campaign and its objective.

Disagree with this article?